30 August 2010
Elan Corporation plc Announces Commencement of Asset Sale Offer to
Purchase up to $186,000,000 of 8 7/8% Senior Fixed Rate Notes Due 2013
and Floating Rate Notes Due 2013| DUBLIN, Aug 30, 2010 (BUSINESS WIRE) --Elan Corporation, plc ("Elan") (NYSE: ELN) announced today that Elan's
wholly-owned subsidiaries, Elan Finance public limited company ("Elan
Finance") and Elan Finance Corp. ("Elan Corp" and together with Elan
Finance, the "Issuers"), commenced an offer to purchase of up to
$186,000,000 aggregate principal amount of their 8 7/8% Senior Fixed
Rate Notes due 2013 (the "2013 Fixed Rate Notes") and their Floating
... |
|
24 August 2010
Preliminary Data in Support of Investigational Anti-JCV Antibody
Assay Published in the Annals of Neurology| -- Clinical studies underway to further evaluate assay's potential to
stratify risk in TYSABRI-treated patients --
WESTON, Mass., Aug 24, 2010 (BUSINESS WIRE) --Biogen
Idec (NASDAQ: BIIB) and Elan
Corporation, plc (NYSE: ELN) today announced data has been published
in the Annals of Neurology on an investigational, two-step assay
to detect anti-JC virus (JCV) antibodies in human serum and plasma. This
assay is currently being evaluated in clinica... |
|
17 August 2010
Elan Corporation, plc Announces Redemption of its Senior Floating
Rate Notes Due 2011| DUBLIN, Aug 17, 2010 (BUSINESS WIRE) --Elan Corporation, plc ("Elan") (NYSE: ELN) announced today that it will
redeem all of the outstanding Senior Floating Rate Notes due 2011 (the
"Notes") of its wholly owned subsidiaries, Elan Finance public limited
company and Elan Finance Corp. (the "Co-Issuers"), of which $300 million
in principal amount is currently outstanding.
The Notes are redeemable at the Co-Issuers' option at a redemption price
equal to 1... |
|
11 August 2010
Elan Corporation plc Announces Pricing of 2016 Senior Notes| DUBLIN, Aug 11, 2010 (BUSINESS WIRE) --Elan Corporation, plc ("Elan") (NYSE: ELN) today announced the pricing
of the offering of US$200 million aggregate principal amount of 8.75%
senior notes due 2016 ("Notes") by its wholly-owned subsidiaries, Elan
Finance public limited company and Elan Finance Corp. The Notes will be
issued at an offering price of 96.0 plus accrued interest, if any, from
August 17, 2010. The offering is expected to close on August 17, ... |
|
11 August 2010
Elan Corporation Plc Announces Intent to Offer US$200m in Aggregate
Principal Amount of 8.75% Senior Notes Due 2016| DUBLIN, Aug 11, 2010 (BUSINESS WIRE) --Elan Corporation, plc ("Elan") (NYSE: ELN) today announced that its
wholly-owned subsidiaries, Elan Finance public limited company ("Elan
Finance") and Elan Finance Corp. ("Elan Corp" and together with Elan
Finance, the "Issuers"), intend to offer, subject to market conditions,
US$200 million in aggregate principal amount of 8.75% senior notes due
2016 (the "New Notes"). The New Notes will be offered to qualified
... |
|
09 August 2010
Elan Provides Update on Initiatives to Further Enhance Balance Sheet
and Operating Performance|
To Reduce Total Indebtednessand Extend Maturity
Profile
Reaffirms Full Year 2010 Financial Guidance
Provides 2011 Cash Flow and OpEx Guidance
Completes Evaluation of Elan Drug Technologies
DUBLIN, Aug 09, 2010 (BUSINESS WIRE) --Elan Corporation, plc ("Elan" or the "Company") (NYSE: ELN) today
announced continued progress on the Company's ongoing efforts to
maximize financial performance and strength, and to position its
... |
|
09 August 2010
Elan And Transition Therapeutics Announce Topline Summary Results Of
Phase 2 Study and Plans for Phase 3 for ELND005 (Scyllo-inositol )|
The AD201 study did not achieve significance on co-primary outcome
measures (NTB and ADCS-ACL)
The study identified a dose with acceptable safety and tolerability
This dose achieved target drug levels in the cerebrospinal fluid
We believe this dose demonstrated a biological effect on amyloid-beta
protein in the cerebrospinal fluid and effects on clinical endpoints
in... |
|
22 July 2010
Elan Reports Second Quarter and First Half 2010 Financial Results| DUBLIN, Jul 22, 2010 (BUSINESS WIRE) -- Elan Corporation, plc today reported its second quarter and first half 2010 financial results.
Elan CEO Kelly Martin commented, "Our second quarter results demonstrate continued progress across our major areas of focus. Tysabri growth increased in terms of net patient additions; our BioNeurology pipeline advanced, including completion of the ELND005 Phase 2 trial and full enrollment of the STRATIFY 1 trial studying the JC virus assay; we also saw recen... |
|
15 July 2010
Elan Corporation, plc Reaches Agreement in Principle for Settlement
of Investigation of Past Zonegran Sales and Marketing Activities| Elan establishes $206.3 million reserve for expected settlement
DUBLIN, Jul 15, 2010 (BUSINESS WIRE) --Elan Corporation, plc (NYSE: ELN) today announced that it has reached an
agreement in principle with the United States Attorney's Office for the
District of Massachusetts with respect to the previously disclosed U.S.
Department of Justice's investigation of sales and marketing practices
for Zonegran (zonisamide), an antiepileptic prescription medicine that
... |
|
08 July 2010
Elan Announces Webcast of Second Quarter 2010 Financial Results| DUBLIN, Jul 08, 2010 (BUSINESS WIRE) --Elan Corporation, plc (NYSE:ELN) announced today that it will host a
conference call on Thursday, July 22, at 8:30 a.m. Eastern Time (ET),
1:30 p.m. GMT with the investment community to discuss Elan's second
quarter 2010 financial results, which will be released before the
European and U.S. financial markets open.
Live audio of the conference call will be simultaneously broadcast over
the Internet and will be ava... |
|
06 July 2010
Eliseo O. Salinas, MD, MSc Joins Elan as Executive Vice President and
Chief Medical Officer| DUBLIN, Jul 06, 2010 (BUSINESS WIRE) --Elan Corporation, plc (NYSE: ELN) today announced that Eliseo Oreste
Salinas, MD, MSc, has joined the company as Executive Vice President and
Chief Medical Officer effective immediately, with responsibility for
leading the company's global development, clinical and medical
initiatives. Dr. Salinas will be based at Elan's South San Francisco
campus, will be a member of the company's executive leadership team, and
... |
|
08 June 2010
Elan to Present at the Goldman Sachs 31st
Annual Healthcare Conference| DUBLIN, Jun 08, 2010 (BUSINESS WIRE) --Elan Corporation, plc (NYSE: ELN) today announced that it will present
at the Goldman Sachs 31st Annual Healthcare Conference on
Tuesday, June 15, 2010, at 2:30 p.m. Eastern Time, 7:30 p.m. GMT.
Interested parties may access a live audio web cast of the presentation
by visiting the Investor Relations section of the Elan website at www.elan.com,
then clicking on the event icon. Following the live webcast, an archived
... |
|
03 June 2010
Elan Corporation, plc Board Announces CEO Agreement| DUBLIN, Jun 03, 2010 (BUSINESS WIRE) --As a key part of its commitment to excellence in corporate governance and prudent executive succession management, Elan Corporation, plc announced today that its Board and Mr. Kelly Martin, Chief Executive Officer have agreed to transition his employment contract from an open-ended agreement to a fixed term agreement.
Under this agreement, Mr. Martin has committed to remain in his current roles as Chief Executive Officer and Director of the company throug... |
|
01 June 2010
Elan to Present at the Jefferies Global Life Sciences Conference| DUBLIN, Ireland, Jun 01, 2010 (BUSINESS WIRE) --Elan Corporation, plc (NYSE: ELN) today announced that it will present at the Jefferies Global Life Sciences Conference on Tuesday, June 8, 2010, at 3:30 p.m. Eastern Time and 8:30 p.m. GMT.
Interested parties may access a live audio web cast of the presentation by visiting the Investor Relations section of the Elan website at http://www.elan.com, then clicking on the event icon. Following the live webcast, an archived version of the presentation... |
|
21 April 2010
Elan Reports First Quarter 2010 Financial Results| DUBLIN, Apr 21, 2010 (BUSINESS WIRE) --Elan Corporation, plc, today reported its first quarter 2010 financial results.
Elan CEO Kelly Martin commented, "The first quarter results demonstrate continued progress for the Company. Both the BioNeurology and EDT businesses are profitable at the operating level and the respective pipelines continue to mature. At the corporate level, the recently announced exploration of a possible separation of EDT will allow us to accurately assess the opportunity a... |
|
19 April 2010
Elan Announces Exploration Of EDT Separation And Board Changes| Elan Drug Technologies
DUBLIN, Apr 19, 2010 (BUSINESS WIRE) --Elan Corporation, plc has decided to explore the possibility of a separation of its Elan Drug Technologies (EDT) business. If executed, any transaction would create two distinct publicly listed companies: Elan BioNeurology and EDT, with each entity being a leader in its field of expertise. The purpose of this exploration is to accurately assess the opportunity and impact on shareholder value.
On an operating basis, both EDT and B... |
|
16 April 2010
Patient-Reported Outcomes Study Shows Improvements In Quality of Life Among Patients After One Year of Treatment with TYSABRI®| Data also showed reduced fatigue and improved cognition
TORONTO – April 16, 2010 – Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced results from a one-year, longitudinal health outcomes study (n=324) in which patients with multiple sclerosis (MS) who received 12 infusions of TYSABRI (natalizumab) reported improvements in quality of life (QoL) measures, as well as reduced fatigue and overall improved cognitive function, as measured by validated tools. The goa... |
|
13 April 2010
Large Body of Data on TYSABRI(R) to Be Presented at Annual Meeting of the American Academy of Neurology| - Data suggests improvement across broad range of functional and quality of life measures -
TORONTO, Apr 13, 2010 (BUSINESS WIRE) --Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced 15 company-sponsored platform and poster presentations at the American Academy of Neurology's (AAN) 62nd Annual Meeting in Toronto, April 10 - 17, 2010. The AAN Annual Meeting is the world's largest gathering of neurologists. The presented data, based on post-hoc analyses and patien... |
|
08 April 2010
Elan Announces Webcast of First Quarter 2010 Financial Results| DUBLIN, Apr 08, 2010 (BUSINESS WIRE) --Elan Corporation, plc (NYSE: ELN) announced today that it will host a conference call on Wednesday, April 21, at 8:30 a.m. Eastern Time (ET), 1:30 p.m. GMT with the investment community to discuss Elan's first quarter 2010 financial results, which will be released before the European and U.S. financial markets open.
Live audio of the conference call will be simultaneously broadcast over the Internet and will be available to investors, members of the news ... |
|
26 March 2010
Elan Announces Filing of Annual Report for Year Ended December 31, 2009| DUBLIN, Mar 26, 2010 (BUSINESS WIRE) -- Elan Corporation, plc (NYSE: ELN) today announced the publication and filing of its Annual Report for the fiscal year ended December 31, 2009. The Annual Report along with Elan's Form 20-F for the year ended December 31, 2009 (as filed with the Securities and Exchange Commission on February 26, 2010) are available on Elan's website at www.elan.com. Elan will provide to all holders of Elan securities, upon request and free of charge, a hard copy of our comp... |
|
25 March 2010
Biogen Idec and Elan Enroll First Patient in Large, Well-Controlled Head-to-Head Study of Multiple Sclerosis Treatments| - Study Aims to Inform Treatment Decisions and Improve Patient Outcomes by Directly Comparing TYSABRI to Copaxone and Rebif -
CAMBRIDGE, Mass., Mar 25, 2010 (BUSINESS WIRE) -- Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced enrollment of the first patient in a global Phase IIIb, randomized, rater-blinded, active-controlled study designed to evaluate switching to TYSABRI(R) (natalizumab) from Copaxone(R) (glatiramer acetate) or Rebif(R) (interferon beta-1a) in pa... |
|
16 March 2010
Elan to Present at the Barclays Capital 2010 Global Healthcare Conference| DUBLIN, Mar 16, 2010 (BUSINESS WIRE) -- Elan Corporation, plc (NYSE: ELN) today announced that it will present at the Barclays Capital 2010 Global Healthcare Conference on Tuesday, March 23, 2010, at 9:00 a.m. Eastern Time and 1:00 p.m. GMT.
Interested parties may access a live audio web cast of the presentation by visiting the Investor Relations section of the Elan website at http://www.elan.com, then clicking on the event icon. Following the live webcast, an archived version of the presentat... |
|
03 March 2010
Elan to Present at the Cowen and Company Healthcare Conference| DUBLIN, Mar 03, 2010 (BUSINESS WIRE) -- Elan Corporation, plc (NYSE: ELN) today announced that it will present at the Cowen and Company Healthcare Conference on Wednesday, March 10, 2010, at 8:45 a.m. Eastern Time and 1:45 p.m. GMT.
Interested parties may access a live audio web cast of the presentation by visiting the Investor Relations section of the Elan website at http://www.elan.com, then clicking on the event icon. Following the live webcast, an archived version of the presentation will ... |
|
28 February 2010
Neuroimaging Technique Supports Reduction in Amyloid-Beta in Brains of Patients Suffering from Alzheimer's Disease Treated with Bapineuzumab| Phase II Study Published Online in LancetNeurology
DUBLIN, Feb 28, 2010 (BUSINESS WIRE) -- Elan Corporation, plc (NYSE: ELN) today announced that findings from a Phase II study which suggested bapineuzumab reduced amyloid-beta deposits in the brains of Alzheimer's disease patients as measured using a neuroimaging technique known as [11C]PiB PET, were published in the February 28, 2010 online edition of Lancet Neurology. Bapineuzumab is a compound under development by Pfizer and Janssen Alzheime... |
|
25 February 2010
Elan Announces Filing of Annual Report on Form 20-F for Year Ended December 31, 2009| DUBLIN, Feb 25, 2010 (BUSINESS WIRE) -- Elan Corporation, plc (NYSE: ELN) today announced the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2009. The Form 20-F is available on Elan's website at www.elan.com. Elan will provide to all holders of Elan securities, upon request and free of charge, a hard copy of our complete audited financial statements included in our Form 20-F.
About Elan
Elan Corporation, plc is a neuroscience-based biotechnology company commit... |
|
10 February 2010
Elan Reports Fourth Quarter and Full-Year 2009 Financial Results| DUBLIN, Feb 10, 2010 (BUSINESS WIRE) -- Elan Corporation, plc today reported its fourth quarter and full-year 2009 financial results and provides financial guidance for 2010.
Elan CEO Kelly Martin said, "during 2009, as the biotechnology industry continued to change significantly, we advanced our multi-year strategy for evolving the company. Our strategic transaction with Johnson & Johnson, now our largest shareholder, accelerated our positioning as a company that vigorously invests in sci... |
|
27 January 2010
Elan Announces Webcast of Fourth Quarter and Full Year 2009 Financial
Results| DUBLIN, Jan 27, 2010 (BUSINESS WIRE) -- Elan Corporation, plc (NYSE: ELN) announced today that it will host a
conference call on Wednesday, February 10, at 8:30 a.m. Eastern Time
(ET), 1:30 p.m. GMT with the investment community to discuss Elan's
fourth quarter and full year 2009 financial results, which will be
released before the European and U.S. financial markets open.
Live audio of the conference call will be simultaneously broadcast over
the Interne... |
|
25 January 2010
Elan Drug Technologies Welcomes the NDA Approval of MS Drug AMPYRA(TM)
(Dalfampridine) Extended Release Tablets| AMPYRA(TM) APPROVED USING ELAN'S PROPRIETARY MXDAS(TM) (MATRIX DRUG ABSORPTION SYSTEM) DRUG DELIVERY TECHNOLOGYDUBLIN, Ireland, Jan 25, 2010 (BUSINESS WIRE) -- Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE:
ELN) today issued the following statement regarding the U.S. Food and
Drug Administration (FDA) approval of AMPYRA(TM) (dalfampridine)
as a treatment to improve walking in patients with multiple sclerosis
(MS). This was demonstrated by ... |
|
11 January 2010
World-Renowned Yogi Baron Baptiste Unveils New Program to Help People with Multiple Sclerosis| -- My MS Yoga is designed to help people better manage one of the most common neurological disorders, which often strikes in the prime of life --CAMBRIDGE, Mass., Jan 11, 2010 (BUSINESS WIRE) -- Baron Baptiste, bestselling author and founder of Baptiste Power Vinyasa Yoga, and Dr. Elliot Frohman, one of the world's leading authorities on multiple sclerosis (MS), have teamed up to develop My MS Yoga, a new program created especially for people with multiple sclerosis. My MS Yoga is an at-home exe... |
|
05 January 2010
Elan to Present at the 2010 J.P. Morgan Healthcare Conference| DUBLIN, Jan 05, 2010 (BUSINESS WIRE) -- Elan Corporation, plc (NYSE: ELN) today announced that it will present at the 28th Annual J.P. Morgan Healthcare Conference, on Wednesday, January 13, 2010, at 9:00 a.m. Pacific Time, noon Eastern Time and 5:00 p.m. GMT.
Interested parties may access a live audio web cast of the presentation by visiting the Investor Relations section of the Elan website at http://www.elan.com, then clicking on the event icon. Following the live webcast, an archived versi... |
|
RSS Feeds | 
E-mail Alerts | 
Contact IR